Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASBP Aspire Biopharma	$0.36 +0.6%	$0.00	$0.22 ▼ $15.80	$17.63M	0.74	7.64 million shs	556,807 shs
ASRT Assertio	$0.67 +0.4%	$0.66	$0.51 ▼ $1.70	$64.46M	0.29	518,886 shs	196,154 shs
CLSD Clearside Biomedical	$0.41 -31.9%	$0.82	$0.32 ▼ $1.65	$46.77M	2.05	389,652 shs	3.61 million shs
OTLK Oncobiologics	$2.18 -5.6%	$1.82	$0.87 ▼ $8.70	$77.54M	0.25	860,024 shs	860,975 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASBP Aspire Biopharma	+0.56%	+8.48%	+12.61%	+35,799,900.00%	+35,799,900.00%
ASRT Assertio	+0.45%	-2.60%	+2.11%	+10.26%	-59.46%
CLSD Clearside Biomedical	-31.87%	-53.67%	-48.10%	-52.33%	-66.12%
OTLK Oncobiologics	-5.63%	+5.31%	+29.76%	+50.34%	-75.64%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ASBP Aspire Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ASRT Assertio	1.8653 of 5 stars	3.5	0.0	0.0	0.0	2.1	0.8	1.3
CLSD Clearside Biomedical	2.1097 of 5 stars	4.1	3.0	0.0	0.0	1.5	0.0	0.0
OTLK Oncobiologics	2.5648 of 5 stars	3.4	4.0	0.0	0.0	2.6	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASBP Aspire Biopharma	0.00	N/A	N/A	N/A
ASRT Assertio	3.00	Buy	$2.75	308.62% Upside
CLSD Clearside Biomedical	2.17	Hold	$4.20	924.39% Upside
OTLK Oncobiologics	2.80	Moderate Buy	$9.60	340.37% Upside

Current Analyst Ratings Breakdown

Latest ASBP, CLSD, ASRT, and OTLK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/18/2025	CLSD Clearside Biomedical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$5.00
7/18/2025	CLSD Clearside Biomedical	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/18/2025	CLSD Clearside Biomedical	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$2.00
7/17/2025	CLSD Clearside Biomedical	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/17/2025	CLSD Clearside Biomedical	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold	$3.00
6/6/2025	OTLK Oncobiologics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$24.00 ➝ $21.00
5/23/2025	CLSD Clearside Biomedical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $5.00
5/20/2025	OTLK Oncobiologics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/19/2025	ASRT Assertio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.50 ➝ $3.50
5/16/2025	CLSD Clearside Biomedical	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$5.00 ➝ $5.00
5/15/2025	CLSD Clearside Biomedical	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$4.00 ➝ $3.00

(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASBP Aspire Biopharma	N/A	N/A	N/A	N/A	($2.17) per share	N/A
ASRT Assertio	$119.00M	0.54	$0.05 per share	13.65	$1.27 per share	0.53
CLSD Clearside Biomedical	$3.76M	8.46	N/A	N/A	($0.51) per share	-0.80
OTLK Oncobiologics	N/A	N/A	N/A	N/A	($3.09) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASBP Aspire Biopharma	-$12.54M	N/A	0.00	∞	N/A	N/A	N/A	-508.70%	N/A
ASRT Assertio	-$21.58M	-$0.32	N/A	22.43	N/A	-25.72%	-24.87%	-10.87%	8/6/2025 (Estimated)
CLSD Clearside Biomedical	-$34.35M	-$0.41	N/A	N/A	N/A	-818.57%	N/A	-114.23%	8/11/2025 (Estimated)
OTLK Oncobiologics	-$75.37M	-$0.91	N/A	N/A	N/A	N/A	N/A	-271.12%	8/13/2025 (Estimated)

Latest ASBP, CLSD, ASRT, and OTLK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q3 2025	OTLK Oncobiologics	-$0.42	N/A	N/A	N/A	$1.66 million	N/A
8/11/2025	Q2 2025	CLSD Clearside Biomedical	-$0.12	N/A	N/A	N/A	$0.50 million	N/A
8/6/2025	Q2 2025	ASRT Assertio	-$0.06	N/A	N/A	N/A	$27.86 million	N/A
5/15/2025	Q2 2025	OTLK Oncobiologics	-$0.55	-$0.40	+$0.15	-$1.50	$0.70 million	N/A
5/14/2025	Q1 2025	CLSD Clearside Biomedical	-$0.12	-$0.11	+$0.01	-$0.11	$0.20 million	$2.33 million
5/12/2025	Q1 2025	ASRT Assertio	-$0.06	-$0.14	-$0.08	-$0.14	$27.52 million	$26.49 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASBP Aspire Biopharma	N/A	N/A	N/A	N/A	N/A
ASRT Assertio	N/A	N/A	N/A	N/A	N/A
CLSD Clearside Biomedical	N/A	N/A	N/A	N/A	N/A
OTLK Oncobiologics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASBP Aspire Biopharma	N/A	0.22	0.22
ASRT Assertio	0.36	1.66	1.35
CLSD Clearside Biomedical	N/A	3.19	3.19
OTLK Oncobiologics	N/A	0.72	0.57

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASBP Aspire Biopharma	19.17%
ASRT Assertio	48.96%
CLSD Clearside Biomedical	18.75%
OTLK Oncobiologics	11.20%

Insider Ownership

Company	Insider Ownership
ASBP Aspire Biopharma	48.00%
ASRT Assertio	4.00%
CLSD Clearside Biomedical	6.20%
OTLK Oncobiologics	4.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASBP Aspire Biopharma	N/A	49.53 million	25.75 million	N/A
ASRT Assertio	20	95.78 million	91.95 million	Optionable
CLSD Clearside Biomedical	30	77.71 million	72.89 million	Optionable
OTLK Oncobiologics	20	33.57 million	31.96 million	Optionable

ASBP, CLSD, ASRT, and OTLK Headlines

Recent News About These Companies

Brokerages Set Oncobiologics, Inc. (NASDAQ:OTLK) Target Price at $9.60

July 14, 2025 | americanbankingnews.com

Oncobiologics, Inc. (NASDAQ:OTLK) Given Average Recommendation of "Moderate Buy" by Analysts

July 11, 2025 | marketbeat.com

Oncobiologics (NASDAQ:OTLK) Trading Up 4.5% - Still a Buy?

July 8, 2025 | marketbeat.com

OTLK Outlook Therapeutics, Inc. - Seeking Alpha

July 2, 2025 | seekingalpha.com

Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer

July 1, 2025 | globenewswire.com

Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event

June 18, 2025 | globenewswire.com

Microsoft shares temp fix for Outlook crashes when opening emails

June 17, 2025 | bleepingcomputer.comB

CFA Institute 2025 Graduate Outlook Survey: Finance Top Career Choice

June 12, 2025 | tmcnet.com

Steve Wilks Pleased With Jets Defensive Outlook

June 12, 2025 | msn.com

Microsoft Outlook to block more risky attachments used in attacks

June 12, 2025 | bleepingcomputer.comB

Outlook’s wet AMD treatment accepted by SMC for NHS Scotland

June 11, 2025 | pharmaceutical-technology.comP

Outlook Therapeutics, Inc.: Outlook Therapeutics Announces SMC Recommendation of LYTENAVA (bevacizumab gamma) for the Treatment of Wet AMD

June 10, 2025 | finanznachrichten.de

Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

June 10, 2025 | globenewswire.com

Highlights | Outlook Planet’s C³ Summit & Awards 2025

June 7, 2025 | outlookbusiness.comO

Natural Gas Price Outlook – Natural Gas Continues to See Same Resistance Level

June 7, 2025 | fxempire.comF

Oilers' Connor McDavid Offers Hilarious Outlook on Crucial Game 1 Moment

June 7, 2025 | msn.com

ChatGPT Business Features Now Include Gmail/Outlook Connectors, Meeting Transcriptions, New Pricing

June 7, 2025 | techrepublic.comT

Outlook Therapeutics introduces Lytenava in Germany & UK for the treatment of wet AMD

June 3, 2025 | pharmabiz.comP

Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD

June 2, 2025 | globenewswire.com

Outlook Therapeutics announces public stock offering

May 24, 2025 | investing.com

Outlook Therapeutics, Inc. Announces Underwritten Public Offering of Common Stock and Warrants

May 24, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASBP, CLSD, ASRT, and OTLK Company Descriptions

Aspire Biopharma NASDAQ:ASBP

$0.36 +0.00 (+0.56%)

As of 07/18/2025 04:00 PM Eastern

Aspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico.

Assertio NASDAQ:ASRT

$0.67 +0.00 (+0.45%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$0.68 +0.00 (+0.59%)

As of 07/18/2025 07:49 PM Eastern

Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

Clearside Biomedical NASDAQ:CLSD

$0.41 -0.19 (-31.87%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$0.42 +0.01 (+1.95%)

As of 07/18/2025 07:58 PM Eastern

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Oncobiologics NASDAQ:OTLK

$2.18 -0.13 (-5.63%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$2.22 +0.04 (+2.06%)

As of 07/18/2025 06:56 PM Eastern

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time